Oramed Pharmaceuticals Inc.
Healthcare / Biotechnology
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Performance
--
Today 0.00 (0.00%)
ORMP
Metrics
Market Cap187M
Latest Price$4.62
Previous Close$4.62
Volume219K
52 Week High$5.19
52 Week Low$2.05
52 Week Change121.84%
Average Volume292K
Revenue0
EPS4.21
P/E Ratio1.086
Forward P/E-57.125
Price/Book0.595
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.74%
Dividend Yield5.47%